JP2020045362A5 - - Google Patents

Download PDF

Info

Publication number
JP2020045362A5
JP2020045362A5 JP2019221419A JP2019221419A JP2020045362A5 JP 2020045362 A5 JP2020045362 A5 JP 2020045362A5 JP 2019221419 A JP2019221419 A JP 2019221419A JP 2019221419 A JP2019221419 A JP 2019221419A JP 2020045362 A5 JP2020045362 A5 JP 2020045362A5
Authority
JP
Japan
Prior art keywords
agonist compound
triple agonist
peg3
diabetes
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019221419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020045362A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020045362A publication Critical patent/JP2020045362A/ja
Publication of JP2020045362A5 publication Critical patent/JP2020045362A5/ja
Pending legal-status Critical Current

Links

JP2019221419A 2013-11-06 2019-12-06 グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物 Pending JP2020045362A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900933P 2013-11-06 2013-11-06
US61/900,933 2013-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016527192A Division JP2017503474A (ja) 2013-11-06 2014-11-06 グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物

Publications (2)

Publication Number Publication Date
JP2020045362A JP2020045362A (ja) 2020-03-26
JP2020045362A5 true JP2020045362A5 (enExample) 2020-11-12

Family

ID=51999398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016527192A Withdrawn JP2017503474A (ja) 2013-11-06 2014-11-06 グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
JP2019221419A Pending JP2020045362A (ja) 2013-11-06 2019-12-06 グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016527192A Withdrawn JP2017503474A (ja) 2013-11-06 2014-11-06 グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物

Country Status (12)

Country Link
US (3) US10131702B2 (enExample)
EP (1) EP3066117B1 (enExample)
JP (2) JP2017503474A (enExample)
KR (1) KR102310392B1 (enExample)
CN (1) CN105829339B (enExample)
AU (1) AU2014345570B2 (enExample)
BR (1) BR112016009995B1 (enExample)
CA (1) CA2929107C (enExample)
EA (1) EA035688B1 (enExample)
MX (1) MX369770B (enExample)
TR (1) TR201902516T4 (enExample)
WO (1) WO2015067716A1 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
UA118558C2 (uk) 2013-05-28 2019-02-11 Такеда Фармасьютікал Компані Лімітед Пептидна сполука
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016066744A2 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP6995042B2 (ja) * 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
TW201833132A (zh) * 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
KR102502040B1 (ko) * 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI809515B (zh) 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US11028123B2 (en) 2018-04-10 2021-06-08 Sanofi-Aventis Deutschland Gmbh Capping of unprotected amino groups during peptide synthesis
WO2019197466A1 (en) 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
SG11202010297UA (en) 2018-05-04 2020-11-27 Novo Nordisk As Gip derivatives and uses thereof
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
US20220088148A1 (en) * 2018-12-21 2022-03-24 Hanmi Pharm, Co., Ltd. A pharmaceutical composition comprising insulin and trigonal glucagon/glp-1/gip receptor agonist
TW202024134A (zh) 2018-12-21 2020-07-01 大陸商江蘇恆瑞醫藥股份有限公司 雙特異性蛋白
PH12022550398A1 (en) 2019-08-19 2023-10-23 Lilly Co Eli Methods of making incretin analogs
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CN111040022B (zh) * 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
US20230158117A1 (en) * 2020-04-20 2023-05-25 Hanmi Pharm. Co., Ltd. Composition for prevention or treatment of hyperlipidemia comprising trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof and method using the same
CN113621045A (zh) * 2020-05-09 2021-11-09 天津药物研究院有限公司 具有双受体激动作用的多肽衍生物及其用途
CA3185637A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
IL299800A (en) * 2020-08-14 2023-03-01 Hanmi Pharm Ind Co Ltd Pharmaceutical compositions containing long-acting conjugates of a triple agonist of the GLP-1/GIP glucagon receptor
IL300017A (en) * 2020-08-14 2023-03-01 Hanmi Pharm Ind Co Ltd A hypotensive pharmaceutical composition that includes a triple activator with activity against all glucagon, GLP-1 and GIP receptors
KR20220041765A (ko) * 2020-09-25 2022-04-01 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
KR20220050818A (ko) * 2020-10-16 2022-04-25 한미약품 주식회사 Gip 유도체, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
KR20220050821A (ko) * 2020-10-16 2022-04-25 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물
JP2023546088A (ja) * 2020-10-16 2023-11-01 ハンミ ファーマシューティカルズ カンパニー リミテッド グルカゴン／ｇｌｐ－１／ｇｉｐ三重作用剤またはその持続型結合体を含むループス関連疾患の予防用または治療用の薬学的組成物
US20230391845A1 (en) 2020-10-30 2023-12-07 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
KR20230126712A (ko) * 2020-12-23 2023-08-30 제지앙 도어 바이오로직스 코., 엘티디. 지속형 글루카곤 유도체
WO2022139538A1 (ko) * 2020-12-24 2022-06-30 한미약품 주식회사 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN117062618A (zh) * 2021-05-26 2023-11-14 联邦生物科技(珠海横琴)有限公司 多激动剂及其应用
CN115572326B (zh) * 2021-06-21 2025-01-10 广东东阳光药业股份有限公司 Glp-1、gcg和gip受体的三重激动剂
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
KR20250017258A (ko) * 2022-05-27 2025-02-04 ㈜ 디앤디파마텍 펩타이드 조성물 및 그 사용 방법
CN117417411B (zh) * 2022-09-28 2025-08-29 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途
KR20250140094A (ko) 2023-01-31 2025-09-24 일라이 릴리 앤드 캄파니 Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025016303A1 (zh) * 2023-07-14 2025-01-23 北京拓界生物医药科技有限公司 Glp-1、gip和gcg受体三激动剂及其应用
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
CN118878642A (zh) * 2024-05-28 2024-11-01 上海辛禧医药科技事务所 一种靶向glp-1r、gipr和gcgr的共激动剂

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288627A (en) 1980-02-12 1981-09-08 Phillips Petroleum Company Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69107455T3 (de) 1990-05-09 2004-09-23 Novozymes A/S Eine ein endoglucanase enzym enthaltende zellulasezubereitung.
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
BR9407424A (pt) 1993-09-07 1996-04-09 Amylin Pharmaceuticals Inc Métodos para regular motilidade gastrointestinal
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5523449A (en) 1995-05-17 1996-06-04 Bayer Corporation Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
ATE316100T1 (de) 1996-06-05 2006-02-15 Roche Diagnostics Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
DK0929567T3 (da) 1996-09-09 2005-06-27 Zealand Pharma As Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese
NZ334595A (en) 1996-09-09 2000-08-25 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998022577A1 (en) 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
AU5850798A (en) 1997-02-05 1998-08-26 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
JP2001525800A (ja) 1997-05-07 2001-12-11 マックス−プランク ゲゼルシャフト ツァー フェルデルンク デア ビッセンシャフテン エー．ファウ．ベルリン 新規のシステイン誘導体、その製造のための方法及びそれを含む医薬品
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
AU749914B2 (en) 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1032587B2 (en) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
WO1999049788A1 (en) 1998-03-30 1999-10-07 Focus Surgery, Inc. Ablation system
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1105460B1 (en) 1998-08-10 2009-10-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
RU2214418C2 (ru) 1998-12-07 2003-10-20 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги glp-1
DK1140145T4 (da) 1999-01-14 2019-07-22 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
ES2343072T3 (es) 1999-01-14 2010-07-22 Amylin Pharmaceuticals, Inc. Exendina para la supresion del glucagon.
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
NZ514916A (en) 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
CN1191273C (zh) 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US6894024B2 (en) 2000-10-20 2005-05-17 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003053460A1 (en) 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
KR20050083713A (ko) 2002-10-02 2005-08-26 질랜드 파마 에이/에스 안정화된 엑센딘-4 화합물
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
BRPI0409600A (pt) 2003-04-29 2006-04-18 Lilly Co Eli análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
US7623530B2 (en) 2003-11-20 2009-11-24 Nokia Corporation Indication of service flow termination by network control to policy decision function
WO2005072045A2 (en) 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
IN2012DN03921A (enExample) 2004-02-11 2015-09-04 Amylin Pharmaceuticals Inc
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
SI1891105T1 (sl) 2005-06-13 2012-07-31 Imp Innovations Ltd Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
ITMI20061607A1 (it) 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
WO2008071010A1 (en) 2006-12-12 2008-06-19 Waratah Pharmaceuticals Inc. Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
EP2124974B1 (en) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
FR2917552B1 (fr) 2007-06-15 2009-08-28 Sagem Defense Securite Procede de regulation de la gigue de transmission au sein d'un terminal de reception
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
GB2455553B (en) 2007-12-14 2012-10-24 Nuaire Ltd Motor mounting assembly for an axial fan
CN101970476B (zh) 2008-01-09 2014-08-27 塞诺菲-安万特德国有限公司 具有超延迟时效特征的胰岛素衍生物
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
SG192405A1 (en) 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
CN102123723B (zh) 2008-06-17 2016-05-25 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
MY158627A (en) 2008-07-31 2016-10-31 Univ Case Western Reserve Halogen-stabilized insulin
WO2010016940A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
DK2370460T3 (da) 2008-12-15 2014-08-04 Zealand Pharma As Glucagon analoger
ES2439499T3 (es) 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
CA2747490C (en) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
EP2376521B1 (en) 2008-12-19 2016-04-13 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US20100240883A1 (en) 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
RU2012101274A (ru) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения глюкагона, активные в отношении рецептора gip
KR101809024B1 (ko) 2009-07-13 2017-12-14 질랜드 파마 에이/에스 아실화 글루카곤 유사체
WO2011080103A1 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
JP2013517307A (ja) * 2010-01-20 2013-05-16 ジーランド ファーマ アクティーゼルスカブ 心臓病の処置
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
US20130053310A1 (en) 2010-03-26 2013-02-28 Novo Nordisk A/S Novel glucagon analogues
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
CA2797431C (en) 2010-04-27 2016-06-21 Zhejiang Beta Pharma Inc. Glucagon-like peptide-1 analogue and use thereof
MX343360B (es) 2010-04-27 2016-11-03 Zealand Pharma As Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
BR112012033225A2 (pt) 2010-06-24 2017-06-20 Zealand Pharma As análogos do glucagon
CN103209711B (zh) 2010-11-09 2016-04-13 诺沃—诺迪斯克有限公司 双-酰化的glp-1衍生物
SG192038A1 (en) 2011-01-20 2013-08-30 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
WO2012130866A1 (en) 2011-03-28 2012-10-04 Novo Nordisk A/S Novel glucagon analogues
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
WO2012150503A2 (en) * 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2707713A2 (en) * 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN103764673A (zh) 2011-06-10 2014-04-30 北京韩美药品有限公司 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用
CN104093735B (zh) 2011-09-23 2018-07-06 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
IN2014CN04401A (enExample) 2011-12-23 2015-09-04 Zealand Pharma As
AU2013255751B2 (en) 2012-05-03 2017-10-05 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
RU2015101699A (ru) * 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Слитые полипептиды и конъюгаты полипептида лиганда рецептора инкретина и fc-области с измененной fc-эффекторной функцией
CN109456400A (zh) 2012-07-23 2019-03-12 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
WO2014140222A1 (en) * 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
AP2016009212A0 (en) 2013-10-17 2016-05-31 Zealand Pharma As Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
CN106029088A (zh) 2014-02-18 2016-10-12 诺和诺德股份有限公司 稳定的胰高血糖素类似物以及用于治疗低血糖的用途
WO2016066744A2 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체

Similar Documents

Publication Publication Date Title
JP2020045362A5 (enExample)
JP2023126965A5 (enExample)
JP2015517459A5 (enExample)
HK1258817A1 (zh) 合成三萜类化合物及用以治病之方法
JP5796959B2 (ja) 関節炎における痛みの治療のためのタペンタドール
JP2015503539A5 (enExample)
AU2012250877B2 (en) Composition and method for treatment of diabetes
JP2012515163A (ja) 糖尿病治療のための組成物及び方法
CN113301889A (zh) Nafld和nash的联合治疗
JP2010516702A5 (enExample)
AU2020201980A1 (en) Combination of FXR agonists
JP2020100623A (ja) 炎症及び疼痛の治療のための組成物及び方法
AU2017339826A1 (en) Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder
JPWO2006057152A1 (ja) タンパク質分解酵素阻害化合物からなる糖尿病治療剤
EP3681537A1 (en) Combinations comprising fxr agonists
TW202114671A (zh) 包含fxr促效劑之治療
RU2019110779A (ru) Новые схемы введения агонистов fxr
WO2017076271A1 (zh) 奥贝胆酸和小檗碱的复方组合物及其应用
JP5627452B2 (ja) 筋肉減少の治療に使用される薬剤の組合せ
CA2950463C (en) Cafestol for treating diabetes
JP7508447B2 (ja) 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸
JP6761347B2 (ja) 脂質異常症治療剤
JP2025505187A (ja) 体重減少の方法および骨格筋量を保存する方法
WO2011141419A1 (en) Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
JP5923044B2 (ja) 活性成分としてｌ−カルニチンまたはプロピオニルｌ−カルニチンを含む慢性静脈不全の予防または治療のための併用組成物